Business Context and Reporting Period
Indaptus Therapeutics, Inc. (INDP) filed a Current Report on Form 8-K dated August 28, 2026. The filing reports the entry into a material definitive agreement to establish an "at the market" equity offering program.
Key Financial Metrics and Agreement Terms
- Offering Capacity: The Company may issue and sell shares of Common Stock with an aggregate maximum offering price of up to $100,000,000.
- Agent: H.C. Wainwright & Co., LLC serves as the sales agent and/or principal.
- Compensation: The Company will pay a placement fee equal to 3.0% of the gross sales price of shares sold by Wainwright as sales agent.
- Financial Performance: The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The Company entered into an Amended and Restated At the Market Offering Agreement on August 28, 2026. This agreement amends, restates, and supersedes the original At The Market Offering Agreement dated June 1, 2022. The $100 million sales limit applies solely to shares sold on or after the execution date of the new agreement; shares sold under the original agreement prior to this date are excluded from this limit.
Outlook, Risks, and Management Commentary
- Sales Flexibility: The Company has no obligation to sell any shares under the agreement. Either the Company or Wainwright may suspend the offering at any time.
- Uncertainty: No assurance is given that the Company will sell any shares, nor regarding the price, number of shares, or dates of any potential sales.
- Regulatory Status: The offering is conducted pursuant to a shelf registration statement on Form S-3 (File No. 333-289573), declared effective on August 20, 2025.
- Legal: The agreement includes customary indemnification and contribution rights for Wainwright and reimbursement for certain legal fees.
Investor Verification Checklist
- Verify the number of authorized but unissued shares available for issuance to ensure the $100 million cap can be fully utilized.
- Confirm the Company's continued satisfaction of eligibility requirements for the use of Form S-3.
- Review the full text of the Amended and Restated At the Market Offering Agreement (Exhibit 1.1) for specific covenants and conditions.
- Monitor future filings for actual sales activity, pricing, and the impact of the 3.0% placement fee on net proceeds.